T0	Participants 46 77	chronic schizophrenic patients:
T1	Participants 170 230	cyproheptadine augmentation of ongoing haloperidol treatment
T2	Participants 248 285	40 chronic schizophrenic in-patients.
T3	Participants 914 1026	chronic schizophrenic patients who are intolerant of extrapyramidal side effects of conventional antipsychotics.